Business Insider22d
Strategic Mergers and Financial Strength: Recursion Pharmaceuticals’ Path to Growth
Analyst Gil Blum of Needham maintained a Buy rating on Recursion Pharmaceuticals (RXRX – Research Report), retaining the price target of $11.00. Don't Miss our Black Friday Offers: Gil Blum’s ...
Business Insider22d
Recursion, Exscientia officially combine to advance drug discovery
Recursion (RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform ...
Yahoo Finance22d
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform ...